RethinkPeptides
ArticlesTopicsResearch

Neurodegenerative Disease Peptides

3 articles in this topic.

Neurodegenerative Disease Peptides

Peptide Therapeutics for Parkinson's: The Evidence

Peptide approaches to Parkinson's disease target alpha-synuclein aggregation and neuroinflammation. Here is what clinical and preclinical research shows.

14 min read|Mar 25, 2026
Neurodegenerative Disease Peptides

NAP Peptide (Davunetide): The Neuroprotective Peptide Story

Davunetide (NAP) is an 8-amino-acid peptide that stabilizes microtubules, reduces tau pathology, and reached Phase 2/3 trials for PSP and cognitive decline.

16 min read|Mar 23, 2026
Neurodegenerative Disease Peptides

Huntington's Peptide Research: Targeting Toxic Proteins

Peptide-based approaches to Huntington's disease target polyglutamine aggregation, deliver drugs across the blood-brain barrier, and offer neuroprotection.

13 min read|Mar 22, 2026

RethinkPeptides

Evidence-based peptide education. No hype, no sales. Just science.

Navigate

All ArticlesTopicsResearch DatabaseEvidence MethodologyDownload DataSearch

About

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of Use

Disclaimer

Content on RethinkPeptides is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Peptides discussed here may not be approved for human use in your jurisdiction.

© 2026 RethinkPeptides. All rights reserved.